Comment from Genentech, Inc.

Summary: Genentech, a biotechnology company, supports the draft guidance on New Approach Methodologies (NAMs) and commends the FDA's flexibility in its approach. They provide specific recommendations to clarify definitions, refine terminology regarding "validation" versus "proof of scientific validity," and ensure the guidance remains practical for diverse drug modalities.